Viral hepatitis screening guideline before biological drug use in rheumatic patients
Yıl: 2016 Cilt: 3 Sayı: 1 Sayfa Aralığı: 25 - 28 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022
Viral hepatitis screening guideline before biological drug use in rheumatic patients
Öz: Biological drugs (tumor necrosis factor inhibitors, rituximab, tocilizumab, abatacept, and tofacitinib) are important treatment alternatives in rheumatology, particularly for resistant patients. However, they may cause hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivation; for instance, HBV reactivation may occur in a patient who is an inactive hepatitis B surface antigen (HBsAg) carrier or who has resolved HBV infection. Therefore, the screening of patients before biological treatment and the application of a prophylactic treatment, particularly with respect to latent HBV infections, are recommended when necessary. This guideline covers pre-treatment screening and follow-up recommendations, if required, with respect to viral hepatitides in rheumatology patients who are planned to be given biological drugs. Although this guideline is prepared for biological disease-modifying antirheumatic drugs (DMARDs), it is recommended to be used also for target-oriented DMARDS and medium-high dose corticosteroids (>7.5 mg prednisolone/day equivalent). It should be considered that the reactivation risk is higher when more than one immunosuppressive drug is used.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- Staren ED, Essner R, Economou JS. Overview of biological response modifiers. Semin Surg On- col 1989; 5: 379-84. [CrossRef]
- Kavanaugh AF. Anti-tumor necrosis factor-al- pha monoclonal antibody therapy for rheuma- toid arthritis. Rheum Dis Clin North Am 1998; 24: 593-614. [CrossRef]
- Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, et al. Safety of synthetic and biological DMARDs: a systematic litera- ture review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014; 73: 529-35. [CrossRef]
- Winthrop KL, Calabrese LH. Let the fog be lifted: screening for hepatitis B virus before biological ther- apy. Ann Rheum Dis 2011; 70: 1701-3. [CrossRef]
- Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infec- tion: new estimates of age-specific HBsAg se- roprevalence and endemicity. Vaccine 2012; 30: 2212-9. [CrossRef]
- Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77-87. [CrossRef]
- Tozun N, Ozdogan OC, Cakaloglu Y, Idilman R, Karasu Z, Akarca US, et al. A nationwide prev- alence study and risk factors for hepatitis A, B, C and D infections in Turkey. The 61th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), Boston, MA- USA: 2010; 789.
- Yilmaz N, Karadag O, Kimyon G, Yazici A, Yilmaz S, Kalyoncu, et al. Prevalence of hepatitis B and C infections in rheumatoid arthritis and anky- losing spondylitis: A multicenter countrywide study. Eur J Rheumatol 2014; 1: 51-4. [CrossRef]
- Jansen TL, Mulder CJ. Rheumatology meets hepatology in 2012: a clinician's guideline for TNF inhibitors in hepatitis B/C virus carriers. Ex- pert Opin Biol Ther 2012; 12: 391-3. [CrossRef]
- Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT, American Gastroenterological Association I. American Gastroenterological As- sociation Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gas- troenterology 2015; 148: 215-9; quiz e16-7.
- Raimondo G, Filomia R, Maimone S. Therapy of occult hepatitis B virus infection and pre- vention of reactivation. Intervirology 2014; 57: 189-95. [CrossRef]
- Kim DK, Bridges CB, Harriman KH, Centers for Disease C, Prevention, Advisory Committee on Immunization P, et al. Advisory committee on immunization practices recommended immu- nization schedule for adults aged 19 years or older--United States, 2015. MMWR Morb Mortal Wkly Rep 2015; 64: 91-2. [CrossRef]
- Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61: 703-11. [CrossRef]
- Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Hwang JP, Davila M, et al. Acute exacerbation and reactivation of chronic hepatitis C virus in- fection in cancer patients. J Hepatol 2012; 57: 1177-85. [CrossRef]
- Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-alpha inhibitors and chronic hepatitis C: a comprehensive literature re- view. World J Gastroenterol 2013; 19: 7867-73. [CrossRef]
| APA | KARADAĞ Ö, KAŞİFOĞLU T, ÖZER B, Kaymakoglu S, KUŞ Y, Inanc M, Keser G, KİRAZ S (2016). Viral hepatitis screening guideline before biological drug use in rheumatic patients. , 25 - 28. |
| Chicago | KARADAĞ ÖMER,KAŞİFOĞLU Timuçin,ÖZER Birol,Kaymakoglu Sabahattin,KUŞ Yeşim,Inanc Murat,Keser Gökhan,KİRAZ Sedat Viral hepatitis screening guideline before biological drug use in rheumatic patients. (2016): 25 - 28. |
| MLA | KARADAĞ ÖMER,KAŞİFOĞLU Timuçin,ÖZER Birol,Kaymakoglu Sabahattin,KUŞ Yeşim,Inanc Murat,Keser Gökhan,KİRAZ Sedat Viral hepatitis screening guideline before biological drug use in rheumatic patients. , 2016, ss.25 - 28. |
| AMA | KARADAĞ Ö,KAŞİFOĞLU T,ÖZER B,Kaymakoglu S,KUŞ Y,Inanc M,Keser G,KİRAZ S Viral hepatitis screening guideline before biological drug use in rheumatic patients. . 2016; 25 - 28. |
| Vancouver | KARADAĞ Ö,KAŞİFOĞLU T,ÖZER B,Kaymakoglu S,KUŞ Y,Inanc M,Keser G,KİRAZ S Viral hepatitis screening guideline before biological drug use in rheumatic patients. . 2016; 25 - 28. |
| IEEE | KARADAĞ Ö,KAŞİFOĞLU T,ÖZER B,Kaymakoglu S,KUŞ Y,Inanc M,Keser G,KİRAZ S "Viral hepatitis screening guideline before biological drug use in rheumatic patients." , ss.25 - 28, 2016. |
| ISNAD | KARADAĞ, ÖMER vd. "Viral hepatitis screening guideline before biological drug use in rheumatic patients". (2016), 25-28. |
| APA | KARADAĞ Ö, KAŞİFOĞLU T, ÖZER B, Kaymakoglu S, KUŞ Y, Inanc M, Keser G, KİRAZ S (2016). Viral hepatitis screening guideline before biological drug use in rheumatic patients. European Journal of Rheumatology, 3(1), 25 - 28. |
| Chicago | KARADAĞ ÖMER,KAŞİFOĞLU Timuçin,ÖZER Birol,Kaymakoglu Sabahattin,KUŞ Yeşim,Inanc Murat,Keser Gökhan,KİRAZ Sedat Viral hepatitis screening guideline before biological drug use in rheumatic patients. European Journal of Rheumatology 3, no.1 (2016): 25 - 28. |
| MLA | KARADAĞ ÖMER,KAŞİFOĞLU Timuçin,ÖZER Birol,Kaymakoglu Sabahattin,KUŞ Yeşim,Inanc Murat,Keser Gökhan,KİRAZ Sedat Viral hepatitis screening guideline before biological drug use in rheumatic patients. European Journal of Rheumatology, vol.3, no.1, 2016, ss.25 - 28. |
| AMA | KARADAĞ Ö,KAŞİFOĞLU T,ÖZER B,Kaymakoglu S,KUŞ Y,Inanc M,Keser G,KİRAZ S Viral hepatitis screening guideline before biological drug use in rheumatic patients. European Journal of Rheumatology. 2016; 3(1): 25 - 28. |
| Vancouver | KARADAĞ Ö,KAŞİFOĞLU T,ÖZER B,Kaymakoglu S,KUŞ Y,Inanc M,Keser G,KİRAZ S Viral hepatitis screening guideline before biological drug use in rheumatic patients. European Journal of Rheumatology. 2016; 3(1): 25 - 28. |
| IEEE | KARADAĞ Ö,KAŞİFOĞLU T,ÖZER B,Kaymakoglu S,KUŞ Y,Inanc M,Keser G,KİRAZ S "Viral hepatitis screening guideline before biological drug use in rheumatic patients." European Journal of Rheumatology, 3, ss.25 - 28, 2016. |
| ISNAD | KARADAĞ, ÖMER vd. "Viral hepatitis screening guideline before biological drug use in rheumatic patients". European Journal of Rheumatology 3/1 (2016), 25-28. |
